Hesperidin PLGA nanoparticles potentiate the efficacy of aPD-1 in treating triple negative breast cancer by regulating CCL2 and ADPN expression in cancer-associated adipocytes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Hesperidin PLGA nanoparticles potentiate the efficacy of aPD-1 in treating triple negative breast cancer by regulating CCL2 and ADPN expression in cancer-associated adipocytes

Published:2024-10 Issue: Volume:140 Page:112759
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Luo Ningchao,Ma Lisha,Ma Ninghui,Wei Jiale,Zhang Hongyan,Jin Wanyu,Li Yujie,Shi Jingbin,Xiong Yang^ORCID

Publisher

Elsevier BV

Reference41 articles.

1. Triple-negative breast cancer: current treatment strategies and factors of negative prognosis;Baranova;J. Med. Life,2022

2. Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer;Hsu;Sci. Rep.,2022

3. Circ_0069094 regulates malignant phenotype and paclitaxel resistance in breast cancer cells via targeting the miR-136-5p/YWHAZ axis;Kong;Thorac. Cancer,2023

4. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer;Schmid;N. Engl. J. Med.,2018

5. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here;Kwa;Cancer,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rhein and hesperidin nanoparticles remodel tumor immune microenvironment by reducing CAFs and CCL2 secreted by CAAs for efficient triple-negative breast cancer therapy;International Immunopharmacology;2024-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP